144 related articles for article (PubMed ID: 7438480)
1. Vitamin D metabolites and their relationship to azotaemic osteodystrophy.
Mason RS; Lissner D; Wilkinson M; Posen S
Clin Endocrinol (Oxf); 1980 Oct; 13(4):375-85. PubMed ID: 7438480
[TBL] [Abstract][Full Text] [Related]
2. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
Offermann G; Schaefer K; Schulz A; Delling G
Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
[TBL] [Abstract][Full Text] [Related]
3. 24,25 dihydroxycalciferol: assay in non-anephric patients on chronic haemodialysis and assessment of its possible pathophysiological role in renal osteodystrophy.
Lambrey G; Nguyen TM; Fournier A; Sebert JL; Kassouf J; de Fremont JF; Marie P; Meunier P; Caillens C; Gueris J; Garabedian M; Balsan S
Proc Eur Dial Transplant Assoc; 1980; 17():548-56. PubMed ID: 6972530
[No Abstract] [Full Text] [Related]
4. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
Coen G; Mantella D; Manni M; Balducci A; Nofroni I; Sardella D; Ballanti P; Bonucci E
Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
[TBL] [Abstract][Full Text] [Related]
5. Low serum levels of 1.25-dihydroxyvitamin D and histomorphometric evidence of osteomalacia after jejunoileal bypass for obesity.
Mosekilde L; Melsen F; Hessov I; Christensen MS; Lund BJ; Lund BI; Sørensen OH
Gut; 1980 Jul; 21(7):624-31. PubMed ID: 7429327
[TBL] [Abstract][Full Text] [Related]
6. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D.
Christiansen C; Christensen MS; Melsen F; Rødbro P; DeLuca HF
Clin Nephrol; 1981 Jan; 15(1):18-22. PubMed ID: 7214748
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic problems relating to azotaemic osteodystrophy.
Chan YL; Posen S
Ann Acad Med Singap; 1982 Jan; 11(1):69-76. PubMed ID: 7073232
[TBL] [Abstract][Full Text] [Related]
8. Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia.
Olgaard K; Finco D; Schwartz J; Arbelaez M; Teitelbaum S; Avioli L; Klahr S; Slatopolsky E
Kidney Int; 1984 Dec; 26(6):791-7. PubMed ID: 6335904
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of metabolites of vitamin D in patients with chronic renal failure (CRF). Consequences for the treatment with 1-alpha-hydroxy-derivatives.
Juttmann JR; Buurman CJ; De Kam E; Visser TJ; Birkenhäger JC
Clin Endocrinol (Oxf); 1981 Mar; 14(3):225-36. PubMed ID: 6973423
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of 24,25-dihydroxy vitamin D in different degrees of chronic renal failure.
Weisman Y; Eisenberg Z; Leib L; Harell A; Shasha SM; Edelstein S
Br Med J; 1980 Sep; 281(6242):712-3. PubMed ID: 7427411
[No Abstract] [Full Text] [Related]
11. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
13. Serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D in patients with uremic bone diseases.
Shen F-H ; Baylink DJ; Sherrard DJ; Shen L; Maloney NA; Wergedal JE
J Clin Endocrinol Metab; 1975 Jun; 40(6):1009-17. PubMed ID: 1133150
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure.
Tessitore N; Venturi A; Adami S; Roncari C; Rugiu C; Corgnati A; Bonucci E; Maschio G
Miner Electrolyte Metab; 1987; 13(1):38-44. PubMed ID: 3587183
[TBL] [Abstract][Full Text] [Related]
15. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
[TBL] [Abstract][Full Text] [Related]
16. Morphological effects of vitamin D and its analogs on bone.
Teitelbaum SL
Am J Clin Nutr; 1976 Nov; 29(11):1300-6. PubMed ID: 998541
[TBL] [Abstract][Full Text] [Related]
17. A simplified assay for dihydroxylated vitamin D metabolites in human serum: application to hyper- and hypovitaminosis D.
Mason RS; Lissner D; Grunstein HS; Posen S
Clin Chem; 1980 Mar; 26(3):444-50. PubMed ID: 6892691
[TBL] [Abstract][Full Text] [Related]
18. [Effect of active metabolites of vitamin D on manifestations of primary hyperparathyroidism].
Riancho JA; Pesquera C; Amado JA; Otero M; Freijanes J; Napal J; González Macías J
Med Clin (Barc); 1989 Oct; 93(10):361-4. PubMed ID: 2607788
[TBL] [Abstract][Full Text] [Related]
19. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.
Ellis HA; Peart KM
J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806
[TBL] [Abstract][Full Text] [Related]
20. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
